My watch list
my.bionity.com  
Login  

Assay for Diagnosis of Ovarian Cancer

© Adobe Stock – Designer491

Ovarian cancer (OC) is a malignant tumour of the ovaries or fallopian tubes and is the most fatal gynaecologic tumour. This technology utilizes new biomarkers in plasma or peritoneal fluid for the diagnosis or prognosis of ovarian cancer.

The concentration of these biomarkers can be measured by an antibody-based proximity extension assay (PEA), alternatively by ELISA-based techniques, or by antibody- or aptamer-based microarrays.

Application fields

One application field of the technology is the diagnosis of ovarian cancer (OC), especially in early stage patients. Another application field is the monitoring of OC patients during or after treatment.

Advantages of the prior art

This new technology improves the diagnosis of ovarian cancer (OC) by solving the following tasks:

  • Diagnosis of early stage ovarian cancer
  • Detection of recurrences during or after treatment of ovarian cancer (staging)
  • Control of therapy efficacy in patients with ovarian cancer, including anti-angiogenic and immune therapies

State of the product development

The product is an antibody-based proximity extension assay PEA) or ELISA. The product includes a calculation of multi marker scores, which can be applied easily by physicians. The product could be implemented in the guidelines for the diagnosis and treatment of OC.

Market potential

Ovarian cancer is one of the most common diseases in females with approximately 239,000 diagnosis and 152,000 deaths per year worldwide (Brett et al., Cancer Biol Med 2017). The highest incidence is in Middle and Eastern Europe with 11.4 cases per 100,000 women. Since there is currently no suitable method for the reliable diagnosis of ovarian cancer in blood samples the inventive method has an enormous market potential for the early detection of both primary and relapsed OC as well as for monitoring therapy efficacy.

Cooperation opportunities

On behalf of its shareholder Philipps-Universität Marburg TransMIT GmbH is looking for licensees or cooperation partners for further development in Europe.

Facts, background information, dossiers
More about TransMIT
More about Universität Marburg
  • White papers

    Assay for Diagnosis of Ovarian Cancer

    This technology utilizes new biomarkers in plasma or peritoneal fluid for the diagnosis or prognosis of ovarian cancer. more

  • News

    The Key that Fits: New Technique To Trace Disease-Related Agents

    In the development of new drugs, photoaffinity labels (PALs) are a versatile tool to investigate the interaction between a receptor and a drug or a ligand. Researchers working with Stephanie Grond at the University of Tübingen and Paultheo von Zezschwitz at the University of Marburg have no ... more

    Proteinbiosynthese: Neuer "Stopp"-Faktor entdeckt

    Einen "essentiellen" zellulären Mechanismus, der an der Übersetzung genetischer Informationen in Proteine beteiligt ist, hat eine junge Forschergruppe um die Heisenberg-Stipendiatin Dr. Heike Krebber entdeckt. Heike Krebber ist Privatdozentin am Institut für Molekularbiologie und Tumorforsc ... more

Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE